Harmony Biosciences Q2 Beat Belies History of Misses
Harmony Biosciences delivered a 30.5% EPS beat in Q2 with $1.50 actual versus $1.15 estimate, generating $0.96 billion in trailing 12-month revenue with 30.3% growth. However, this single strong quart
Harmony Biosciences Q2 Beat Belies History of Misses
NEW YORK, September 3 —
Harmony Biosciences Holdings, Inc. (HRMY) posted a 30.5% EPS beat in Q2 2026, but that single strong quarter lands against two consecutive sharp misses, and the market, for now, is choosing to remember the misses. The stock sits at 6.4x forward earnings despite 30.3% revenue growth, a configuration that looks like an opportunity until the prior-quarter wreckage comes into frame.
- Q2 EPS of $1.50 vs. $1.15 consensus, a 30.5% positive surprise; filed with the SEC on August 4, 2026.
- Trailing twelve-month revenue of $0.96bn, up 30.3% year-over-year, with $183mn in free cash flow.
- Net cash of roughly $510mn, about 20% of the company's $2.50bn market cap, against a 6.4x forward P/E.
One Product Doing Serious Work
Harmony's entire commercial operation runs through a single molecule: WAKIX (pitolisant), approved for excessive daytime sleepiness in narcolepsy patients, distinguished from older-generation therapies by a histamine H3 receptor antagonist mechanism. Every dollar of the $0.96bn in trailing revenue flows from U.S. WAKIX sales alone. That concentration is the company's greatest strength and its most obvious risk. The 75.4% gross margin signals real pricing power in a disease area where alternatives are limited; a single formulary decision or a competitive approval could reprice the entire business overnight. The pipeline (Phase 3 trials in Prader-Willi Syndrome and Fragile X, plus an orexin-2 agonist in earlier development) exists precisely to address that fragility, but those readouts are not this year's story.
The Misses the Beat Cannot Erase
Before Q2's $1.50 actual versus $1.15 estimate, the two preceding quarters produced misses of -16.0% and -46.9%, the latter representing the worst shortfall in the trailing four-quarter window. That sequence is the mechanism behind the 6.4x forward multiple: analysts who have been burned twice on a single-product pharmaceutical will apply a discount that a one-quarter beat cannot arithmetically undo. Short sellers holding 9.5% of the float, a structurally significant position, are making the same inference. The arithmetic of $183mn in free cash flow and a $510mn net cash cushion argues the valuation is disconnected from the business's cash generation; the -46.9% miss argues the earnings line is genuinely hard to model, and both things can be true simultaneously.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| HRMY | $2.5B | 6.4x | +18.1% |
| KYMR | $9.7B | n/a | +181.1% |
| INBX | $1.8B | n/a | +350.8% |
| KROS | $220M | n/a | -27.8% |
| PCVX | $9.1B | n/a | +91.5% |
| RLAY | $4.1B | n/a | +362.8% |
The Number That Changes the Thesis
Consensus carries a $47.36 price target, roughly 10.5% above current levels, modest ambition for a company growing revenue at 30%. The bullish case is straightforward: that multiple on a business with institutional ownership at 99.6% of the float and $510mn in net cash is a valuation anomaly that would ordinarily attract acquirers. The bearish case is equally simple: two quarters of significant misses followed by one beat does not establish a trend. The next quarterly print is the decisive data point. If HRMY delivers a second consecutive beat at or near the Q2 magnitude, the discount becomes indefensible. If it misses again, the shorts are right and the multiple reflects fair skepticism, not opportunity. Run the free Harmony Biosciences Holdings, Inc. deep-dive →
Current fundamentals, valuation and filing history for Harmony Biosciences Holdings, Inc. (HRMY) are tracked on its Basis Report page.
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
Did Harmony Biosciences beat Q2 earnings?
Harmony posted a 30.5% EPS beat in Q2 2026, delivering $1.50 per share versus $1.15 consensus estimate. The company generated $0.96 billion in trailing 12-month revenue with 30.3% year-over-year growth and $183 million in free cash flow.
Why is Harmony stock trading at a low multiple despite growth?
The 6.4x forward P/E reflects analyst skepticism built by two consecutive misses: -16.0% in one quarter and -46.9% in the worst shortfall of the trailing four-quarter window. One beat does not arithmetically erase that damage; the market is waiting to see if this quarter establishes a new trend or proves to be an outlier.
What is WAKIX and why does it matter?
WAKIX (pitolisant) is Harmony's sole product, generating all $0.96 billion in revenue, approved for excessive daytime sleepiness in narcolepsy patients and distinguished by a histamine H3 receptor antagonist mechanism. The drug delivers 75.4% gross margins, showing real pricing power, but concentrating all revenue in a single molecule creates vulnerability to formulary decisions or competitive approvals.
Does Harmony have financial cushion?
Harmony holds approximately $510 million in net cash, roughly 20% of the company's $2.50 billion market cap. This cash cushion supports Phase 3 trials in Prader-Willi Syndrome and Fragile X, though the pipeline remains early-stage.
What determines Harmony's valuation from here?
The next quarterly print is the decisive data point for the thesis. If HRMY delivers a second consecutive beat at or near Q2 magnitude, the 6.4x discount becomes indefensible; if it misses again, the short position (9.5% of float) and the low multiple are validated as appropriate skepticism.
Harmony Biosciences posted a 30.5% EPS beat in its most recently reported quarter on the back of 30% revenue growth, yet nearly one in ten shares are held short and the stock trades at just 6.4x forward earnings — a discount that looks less like opportunity and more like the market's memory of two consecutive quarters of sharp misses.